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care expenses concerning osteoarthritic patients decreases during the semester 
following a spa therapy.
PMS88
Productivity LoSS due to Low Back Pain: reSuLtS froM SwediSh 
regiSterS
Jonsson E1, Olafsson G1, Fritzell P2, Hägg O3, Borgström F1
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Objectives: This study aimed to evaluate the trajectory of losses to paid produc-
tion in patients with low back pain with/without radiant pain (LBP) before and after 
the start of the condition onset, and before and after surgery for LBP. MethOds: 
Patients visiting healthcare providers, or receiving health insurance benefits, with a 
LBP-diagnosis in region of Västra Götaland in 2008-2012 were identified in the VEGA 
database, along with patients who underwent surgery during 2000-2012, identi-
fied from the national spine surgery register “SWESPINE”. Data from additional 
Swedish national registers including inpatient and outpatient care, drug prescrip-
tions, socioeconomics and social security were extracted. Days of sick leave and 
early retirement were summed and multiplied with the per-day gross wage to obtain 
total cost. Two patient-groups were created and analysed separately; those who 
did not undergo surgery and those with surgery. Patients without surgery were 
followed for 3 years before/after the “onset-date”, defined as the first observed 
event with a specific LBP-diagnosis, and patients with surgery 3 years before/after 
surgery date. Results: More than 145,000 patients were identified. In patients 
who did not undergo surgery, monthly productivity cost gradually increased dur-
ing the 1-12 months pre-onset date, peaking at 1 month post-onset date (€ 1,995), 
levelling at a rate higher in the 12-36 months post-onset (average € 1,022/month) 
compared to 12-36 months pre-onset (average € 605/month). In the surgery-group, 
a similar trajectory was found; on average € 1,345/month in the 12-36 months pre-
surgery, peaking at 1 month post-surgery (€ 2,920), levelling at € 1,469/month in 12-36 
months post-surgery. Women showed higher productivity cost than men, as well 
as older patients compared to younger. cOnclusiOns: Indirect costs related to 
LBP are high. Interventions with the potential of improving treatment of LBP can 
be expected to reduce the burden of disease. Acknowledgements: The study was 
financed with an unrestricted grant from Medtronic.
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Objectives: The aim of this study was to examine the impact of etanercept (ETN) 
therapy on work productivity in patients with rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and psoriasis (PS), who are not responding to disease-modifying 
antirheumatic drugs (DMARDs) in prospective real world observation in the Czech 
Republic. The data collection is still ongoing. MethOds: Work productivity was 
examined in 17 working patients (6-RA, 8-PsA and 6-PS) using the Health and Work 
Productivity Questionnaire (HPQ) before ETN treatment initiation and after 3 months 
of treatment. Productivity losses were monetized using average wage calculated by 
friction cost (FC) and human capital (HC) approaches. We also measured health-
related quality of life (HRQoL) using the EQ-5D-3L questionnaire. Results: The 
baseline values of absenteeism (Ab), presenteeism (Pr) and total HPQ score were 
0.062, 0.754 and 0.693, respectively. Ab decreased to 0.000 while Pr and total HPQ 
score significantly increased to 0.899 (p = 0.0456 and 0.006) after 3 months of treat-
ment. The average productivity loss per patient was € 1,705 (FC) or € 38,819 (HC) at 
the baseline and it decreased to € 573 (FC) or € 12,971 (HC) after the three months 
of ETN therapy. The largest change in total HPQ score was 0.211 in RA (PsA-0.197, 
PS-0.166). Consequent changes in productivity losses were equal to -€ 1,175 (FC) 
or -€ 25,495 (HC) in RA, -€ 1,062 (FC) or -€ 16,536 (HC) in PsA, and -€ 921 or -€ 35,743 
(HC) in PS. The 3-months ETN therapy also significantly increased the HRQoL: the 
baseline EQ-5D-3L index of 0.659 increased to 0.880 (p< 0.001) and EQ-VAS score of 
39.5 increased to 70.9 (p< 0.001). cOnclusiOns: Modern biological anti-TNF 
(etanercept) therapy has proved to substantially decrease the negative effect of RA, 
PsA and PS on patients’ work productivity leading to lower productivity costs and 
also improvement of theirs quality of life.
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Objectives: The objective of this study was to describe the real-world use of 
rituximab, specifically through examining dispensing frequency among patients 
with rheumatoid arthritis (RA) in England. MethOds: A longitudinal, retrospective 
cohort study was conducted using the Hospital Treatment Insights (HTI) database, 
which links pseudonymised patient data with hospital pharmacy dispensing. HTI 
includes data from January 2010 to September 2014. Included patients were adults 
with RA, defined using ICD-10 codes, who received ≥ 4 dispenses (2 courses) of 
rituximab, with the first course completed within 4 weeks of the index dispense. In 
line with the Summary of Product Characteristics for rituximab, patients must have 
received 1000mg at the index dispense. Any patient with a diagnosis of haematologi-
cal cancer at or prior to index was excluded. Results: One thousand three hundred 
and eighty-one patients had sufficient data to determine dispensing frequency. 
The majority of included patients were female (78.9%), aged 53 and above (60.8%), 
and were dispensed rituximab by a rheumatologist (where consultant type could 
be identified). Two courses of rituximab was the most common number of courses 
received, though some patients received up to 7 courses. The median time between 
courses was found to change with subsequent courses, decreasing from 37.0 weeks 
Objectives: Telerehabilitation after Total Knee Replacement (TKR) showed to be 
not inferior to standard rehabilitation (SR) in clinical outcomes in patients without 
complication related to TKR surgery. Both utilities and cost-utilities are currently 
unexplored for telerehabilitation. The aim of this economic evaluation was to assess 
the potential cost-utility of a mixed telerehabilitation-SR (TR-SR) versus SR pro-
gramme. MethOds: A Markov model simulated the natural progression of TKR, 
assuming telerehabilitation is not influencing transition probabilities and HRQOL. 
Revision risk and utilities were calculated from patient-level data from the multicen-
tre KAT trial, respectively employing parametric survival and linear regression mod-
els. Published literature provided the remaining state-transition probabilities; while 
rehabilitation and transportation costs were identified adopting Ita-NHS perspective 
and monetized employing Italian tariffs. The patients without complication were 
assigned to the TR-SR programme and received half of the sessions in SR and half 
in telerehabilitation regime. Patients with any complication followed the SR. Costs 
and effects were adjusted applying half-cycle correction and an annual discount rate 
of 3%. Probabilistic sensitivity analysis (PSA) described the parameters uncertainty 
and one-way sensitivity analysis assessed the robustness of our assumption for 
HRQOL. Results: Both SR and TR-SR were assessed using a cohort of 1000 patients 
with the KAT trial features (70 years old, 44% male and 19% had any complication). 
The mean±95%CI difference between TR-SR and SR was -215.33±€ 10.64 (the mean 
(SE) lifetime healthcare costs were € 1,033.81 (€ 21.97) for SR and € 818.44 (€ 13.82) for 
SR-TR). The mean (SE) lifetime QALY was 9.69 (0.003). If telerehabilitation at least 
will not decrease the utilities observed in SR, the probability that telereahabilita-
tion is cost-saving (WTP:0€ per QALY) is 90%. cOnclusiOns: SR-TR could be cost-
effective for the Ita-NHS if it does not impair the patients’ HRQOL. Specific utilities 
for telerehabilitation after TKR and further sensitivity analyses are required to relax 
our assumptions.
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Objectives: Campylobacteriosis is one of the most important human foodborne 
infections, attributed to broiler chicken consumption in about 30% of cases. In a 
recently published cost-utility model of potential Campylobacter control measures 
in the EU-27, model assumptions on disease burden and cost of illness were driven 
by data from the Netherlands. The aim of our work was to gather country-specific 
cost of illness estimates, to generate a conservative estimate of Campylobacter 
related disease burden expressed in QALYs, and to re-assess the cost-effectiveness 
of control measure options. MethOds: Data from the Netherlands on productivity 
loss and direct healthcare costs were corrected for country-specific gross average 
wages and total health expenditure per capita, respectively. Health burden due to 
acute gastroenteritis, Guillain-Barré syndrome, and reactive arthritis were estimated 
from published data. Inflammatory bowel disease and irritable bowel syndrome 
were omitted, in line with a WHO opinion. Results: Based on the adapted model, 
the EU-wide implementation of the available and acceptable measures against 
Campylobacter in indoor broiler chicken would be a dominant strategy as com-
pared to the current practice, yielding 26400 QALY gain and 85 million EUR cost 
saving each year. The expected cost saving is due to the decrease of productivity 
loss (69%) and direct healthcare costs (31%). As the investigated strategy is not to 
be reimbursed by healthcare payers, the societal perspective is justified. The poster 
also presents a strategic pricing exercise on bacteriocin treatment in the UK and in 
Hungary (an intervention option currently under development). cOnclusiOns: 
Implementation of the investigated control strategy would be dominant at the EU-27 
level. The cost-effectiveness of add-on bacteriocin treatment in the UK could not be 
justified at the assumed price level. Public health, and also the allocative efficiency 
of public health budgets, could benefit from the application of HTA methodology 
in food safety and nutritional policies.
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Objectives: To describe the cost of ambulatory health care expenses of osteo-
arthritic patients before and after a spa therapy between 2006 to 2011 among the 
French state employees. MethOds: The study is based on patients covered by 
Mutualité de la Fonction Publique Services (MFPS) Health Insurance Company. All 
patients older than 49 years, treated with a spa therapy during 2006-2011 period 
and who have not been treated by spa therapy since at least 2 years were selected 
and considered as « new spa-goers ». The study focused on « osteoarthritic patients 
» defined as those treated by a physiotherapist and/or a rheumatologist during the 
semester before the spa therapy. Data came from MFPS database used to manage 
the reimbursement of health care expenses. Data were collected on a monthly 
basis: medical and paramedical fees, drugs expenses, biological and X-Ray fees. All 
expenses aggregated costs met by National Health Insurance Company (CNAMTS), 
Complementary Health Insurance Company and patients. Statistical analysis were 
done using Stata v11 software. The expenses distribution were compared using 
the Wilcoxon test (p value < 0.05). Results: Among 10,540 patients treated by spa 
therapy, 4,429 osteoarthritic patients (8,072 spa therapy) were selected. The mean 
level of expenses was 1,714.86 € during the semester before and 1,529.33 € after 
the spa therapy (p< 0.001). This decrease (-185.53 € , -10.8%) concerns physiothera-
pists fees (- 93.77 € , -41.7%), drugs expenses (-26.70 € , -5.1%), rheumatologists fees 
(-15.63 € , -42.2%), X-Ray (-17.68 € , -19.7%), GPs fees (-13.33 € , -7.1%) and neurolo-
gists fees (-1.66 € , -26.9%). These decreases are greater among the 50-64 years old 
(-219.58 € , -13.7%) and after the first spa therapy (-206.92 € , -12.8%), but remains 
significant after next spa therapy. cOnclusiOns: In France, ambulatory health 
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Objectives: The New Medicine Service (NMS) is a national community pharmacy 
service to support medicines-taking in people starting a new medicine for defined 
long-term conditions. The study investigated the expansion of NMS for patients with 
gout newly prescribed allopurinol as urate lowering therapy(ULT). Non-adherence 
with ULT is > 60% in the UK MethOds: A probabilistic cost-effectiveness analysis 
from a NHS perspective was conducted to compare NMS (two follow-up consul-
tations to identify and resolve medicines problems) with standard practice (SP) 
(usual supply without further follow-up).Treatment success was defined as patients 
reaching serum-uric-acid-levels < 6mg/dL (sUA-controlled). A Markov model was 
developed to generate incremental cost-effectiveness ratios (ICER). Three health-
states were included: sUA-controlled; sUA-uncontrolled; death. sUA-uncontrolled is 
associated with more acute gout attacks, higher mortality and is more likely in non-
adherent patients. Cycle length was 1 year with a life-time horizon. Transition prob-
abilities, resource use and utilities were derived from published studies. Costs and 
utilities were discounted at 3.5%. The results were plotted on an ICER-scatter-plane 
and presented as a cost-effectiveness acceptability curve (CEAC). Results: mean 
(95% CI) cost per patient- NMS: £2569.43 (2203.69, 2935.17); SP: £2595.39 (2229.63, 
2961.14) and mean (95% CI) QALYs generated per patient- NMS: 10.39 (10.10, 10.68) 
SP: 10.34(10.06,10.60) suggested that NMS dominated SP with increased QALYs (0.058 
(-0.0008, 0.1168)) and reduced costs (-£25.96 (-81.37, 29.44). There was a 83.3% prob-
ability that NMS dominated SP and 98.4% probability that NMS was cost-effective 
at £20000 per QALY ceiling willingness-to-pay. cOnclusiOns: NMS appears to be 
cost-effective when initiating ULT. It was assumed NMS would increase ULT adher-
ence by 11% as in other diseases. NMS remained dominant down to an adherence 
increase of 5.4%. Reasons for ULT nonadherence matched the intervention design 
but further work is needed to assess the actual effectiveness of NMS in ULT.
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bAckgROund: Compliance to therapy is a widespread public health concern espe-
cially for chronic diseases, such as osteoporosis, as it is associated with increased 
morbidity and mortality due to fragility fractures. Objectives: To conduct the sys-
tematic review of clinical trials evaluating adherence to oral and parenteral bispho-
sphonates in patients with postmenopausal and senile osteoporosis. MethOds: 
We searched publications in PubMed and the Cochrane Library in November 2014. 
Studies of any design published in English were considered. The following criteria 
of medication adherence were taken into account: persistence rate (percentage 
of patients remaining on therapy at a given time). compliance rate (percentage 
of patients act in accordance with the prescribed interval and dose of a dosing 
regimen), medication possession ratio (proportion of doses dispensed in relation 
to doses prescribed), persistence (number of days from initiation to discontinuation 
of therapy). Results: Thirty one publications were included (1 meta-analysis, 5 
systematic reviews, 14 RCT, 7 prospective cohort studies, and 4 retrospective cohort 
studies). Original studies were heterogeneous in terms of drugs, treatment regimes, 
follow up periods, and measurements of adherence, so quantitative meta-analysis 
was not possible. The 12 months persistence rate for patients receiving oral bis-
phosphonates varies in the range of 16-78% in real practice and 54-88% in RCT. The 
persistence rate for parenteral bisphosphonates at 12 months was 86% in one real 
practice study, and 95% in one RCT. cOnclusiOns: Methodology of evaluating 
compliance/adherence or persistence is heterogeneous among the studies of bis-
phosphonates treatment in patients with osteoporosis. Сompliance and persistence 
with bisphosphonates are poor and suboptimal in real practice. The parenteral 
administration of bisphosphonates seems to have enhanced adherence when com-
pared with oral bisphosphonates.
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Objectives: To describe treatment discontinuation among postmenopausal 
women initiating denosumab or monthly oBPs in routine clinical practice in 
Bulgaria. MethOds: This retrospective chart review, conducted in 12 Bulgarian 
endocrinology or rheumatology practices, included postmenopausal women ≥ 50 
years old initiating denosumab or monthly oBPs between 1-Oct-2011 and 30-Sep-
2012, followed up to 24 months after treatment initiation. For both denosumab and 
monthly oBPs, discontinuation date was taken from the patients’ medical records 
(including any switch to another treatment/dosing regimen). If no such date was 
recorded, patients’ were assumed to have continued on treatment. Denosumab per-
sistence at 12, 18 and 24 months was defined as receiving the subsequent injection 6 
months +60-days after the previous injection. Persistence to monthly oBPs could not 
be calculated. Results: A total of 224 women initiating denosumab and 217 initiat-
ing monthly oBPs met the inclusion criteria. Of these, 57 (25%) initiating denosumab 
and 38 (18%) initiating monthly oBPs had experienced ≥ 1 prior OP fracture; 3 (1.3%) 
initiating denosumab and 8 (3.7%) initiating monthly oBPs experienced ≥ 1 OP fracture 
during the follow-up period. At treatment initiation, mean (SD) BMD T-scores for the 
denosumab and oBPs groups were -3.2 (±0.65) and -3.0 (±0.57) at the lumbar spine, -3.2 
(±0.69) and -2.8 (±0.73) at the total hip and -2.6 (±0.71) and -2.4 (±0.77) at the femoral 
neck. Within the 24-month follow-up, 4.5% of women initiating denosumab and 56.2% 
initiating monthly oBPs discontinued treatment; median (interquartile range) time 
to discontinuation, 729.0 (728.3„Ÿ729.0) and 367.0 (354.0„Ÿ484.8) days, respectively. 
Denosumab persistence was 100%, 99.1% and 98.7% at 12, 18 and 24 months, respec-
between the first and second courses to 23.9 weeks between the sixth and seventh 
courses. Subgroup analyses performed in 115 patients receiving rituximab in line 
with National Institute for Health and Care Excellence (NICE) guidance, i.e. after 
prior biologic therapy, demonstrated that dispensing frequency in this group did 
not differ markedly from the whole cohort. cOnclusiOns: The findings of this 
analysis show that long-term rituximab use in the National Health Service differs 
from that assumed by NICE in previous appraisals of biologics in RA, with possible 
implications for future assessments of cost-effectiveness.
MuScuLar-SkeLetaL diSorderS – Patient-reported outcomes & Patient 
Preference Studies
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Objectives: To determine 12-month persistency rates for five commonly-used 
anti-inflammatory biologic agents and identify cost and patient characteristics 
associated with persistency. MethOds: Using an administrative claims database 
for > 30 U.S. commercial health plans (9.2 million members), we identified patients 
aged ≥ 18 years who had ≥ 1 claim for a biologic anti-inflammatory agent (tocili-
zumab, certolizumab pegol, etanercept, adalimumab or infliximab) in 2012 or 2013 
and were continuously enrolled for ≥ 15 months after the initial claim date. We 
determined rates of 12-month persistency overall and by drug, diagnostic indication, 
comorbidity count, route of drug administration, and copayment level. Results: 
A total of 15,834 patients met study criteria. Twelve-month persistency rates were 
70.7% among all patients and 51.5% among patients new to therapy. Persistency was 
highest for infliximab (82.3%), followed by adalimumab (66.1%), certolizumab pegol 
(65.5%), etanercept (65.1%), and tocilizumab (60.6%) (P< 0.001). Higher persistency 
was observed for drugs administered intravenously (81.2%) versus subcutaneously 
(65.6%) (P< 0.01). Persistency was higher in patients with Crohn’s disease/ulcera-
tive colitis (79.1%) than in patients with rheumatoid arthritis (67.0%) or psoriatic 
conditions (61.4%) (P< 0.01) and was also higher in patients with no comorbidities 
than in those with 1 or ≥ 2 (P< 0.01). Highest persistency was observed for patients 
with a mean plan copayment of $50 to < $100, followed by $0 to< $50, $100 to < $300, 
and ≥ $300 (P< 0.01). This trend was observed irrespective of intravenous or subcu-
taneous route of administration. cOnclusiOns: Twelve-month persistency with 
anti-inflammatory biologic agents was highest in patients with Crohn’s disease 
and lower in patients new to therapy and in those with comorbidities. Persistency 
was higher for drugs administered intravenously versus subcutaneously. Although 
the relationship between persistency and cost-sharing was not linear, copayments 
≥ $300 were associated with lowest persistency. Patient and plan characteristics 
should be considered in efforts to improve patient adherence to therapy.
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Objectives: Non-adherence to treatment represents an important public health 
problem. Little is known about the frequency with which patients fail to fill initial 
prescriptions (“primary non-adherence”) and its predictors. Our aim was to esti-
mate primary non-adherence to antiosteoporotic treatment and its associated fac-
tors. MethOds: Prospective cohort study comprising men and women ≥ 50 years 
(ESOSVAL cohort) who started antiosteoporotic treatment between 2009 and 2011. 
Data were obtained by linking diverse electronic health records of the Valencia region, 
which allows the differentiation between prescriptions (what the doctor prescribed) 
and dispensing (what the patient fills from the pharmacy) at individual level. A 
descriptive analysis was performed according to primary non-adherence and a mul-
tivariable logistic regression analysis to assess factors associated (patient characteris-
tics and medication related covariates) with primary non-adherence. Results: From 
2260 treated patients of the ESOSVAL cohort 712 (31.5%) were new users. Of those, 80% 
were female, mean age 65.4 (64.7-66.1), 22.3% had previous osteoporotic fracture, and 
22.2% had a 10-year risk of hip fracture ≥ 3. Most of the patients (84.1%) were treated 
with bisphosphonates. Regarding primary non-adherence, 6.5% of patients did not fill 
their first prescription at the pharmacy. These patients were more likely to be younger, 
to use medications that decrease bone mass, to have concomitant medications, to 
have high risk of hip fracture (assessed by FRAX), and hospitalizations in the last year. 
Factors independently associated with primary non-adherence were being over 65 
years old (OR:0.29; CI95%:0.13;0.64) compared to the 50-65 year-old age stratum and 
polypharmacy (OR:0.45; CI95%: 0.24;0.86). cOnclusiOns: Primary non-adherence 
was substantial although lower than that observed in other therapeutic areas. Very 
few characteristics were independently associated with primary non-adherence. Our 
findings suggest that those at higher risk for osteoporotic fracture and older were 
more likely to be non-adherent. Further research is needed regarding primary non-
adherence predictors.
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